Related Experiment Video

Updated: Apr 6, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K

Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutations

Simone M Goldinger1, Carla Murer1, Pascale Stieger1

  • 1University Hospital, Department of Dermatology, Zurich, Switzerland.

EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]
|July 29, 2015
PubMed

Insights

Targeted therapies like BRAF and MEK inhibitors have improved outcomes for advanced melanoma patients with specific mutations. Combinations of these kinase inhibitors are expected to further enhance survival rates and progression-free survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Melanoma is a complex cancer with diverse molecular features.
  • Targetable mutations, such as BRAF and c-KIT, are key in melanoma.
  • Kinase inhibitors represent a significant advancement in melanoma treatment.

Purpose of the Study:

  • To review the efficacy of targeted kinase inhibitors in advanced melanoma.
  • To highlight the impact of BRAF and MEK inhibitors on patient survival.
  • To discuss the potential of combination therapies for improved outcomes.

Main Methods:

  • Review of clinical trial data for targeted therapies.
  • Analysis of BRAF and MEK inhibitors in melanoma treatment.
  • Examination of efficacy in relation to specific mutations (e.g., BRAF, NRAS).

Main Results:

  • BRAF inhibitors (vemurafenib, dabrafenib) improve survival in BRAF-mutated melanoma.
  • MEK inhibitors (trametinib, MEK 162) demonstrate efficacy, including in NRAS-mutated melanoma.
  • Targeted therapies offer specific treatment options based on molecular profiles.

Conclusions:

  • Kinase inhibitors have transformed advanced melanoma treatment.
  • Combination therapies hold promise for further improving overall survival and progression-free survival.
  • Personalized medicine based on molecular mutations is crucial for melanoma management.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.8K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K